These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 25271285)

  • 1. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
    Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
    mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
    Zhou P; Hong J
    Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
    Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
    mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
    Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC.
    Erwin AL
    Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27235477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay of Klebsiella pneumoniae
    Mostafavi M; Wang L; Xie L; Takeoka KT; Richie DL; Casey F; Ruzin A; Sawyer WS; Rath CM; Wei JR; Dean CR
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30381354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
    Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
    Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent LpxC Inhibitors with
    Krause KM; Haglund CM; Hebner C; Serio AW; Lee G; Nieto V; Cohen F; Kane TR; Machajewski TD; Hildebrandt D; Pillar C; Thwaites M; Hall D; Miesel L; Hackel M; Burek A; Andrews LD; Armstrong E; Swem L; Jubb A; Cirz RT
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
    Liu F; Ma S
    Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the gram-negative pathogen Pseudomonas aeruginosa.
    Caughlan RE; Jones AK; Delucia AM; Woods AL; Xie L; Ma B; Barnes SW; Walker JR; Sprague ER; Yang X; Dean CR
    Antimicrob Agents Chemother; 2012 Jan; 56(1):17-27. PubMed ID: 22024823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
    Zhang J; Zhang L; Li X; Xu W
    Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
    Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
    J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based discovery of LpxC inhibitors.
    Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
    McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial activities and characterization of novel inhibitors of LpxC.
    Clements JM; Coignard F; Johnson I; Chandler S; Palan S; Waller A; Wijkmans J; Hunter MG
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1793-9. PubMed ID: 12019092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin.
    McClerren AL; Endsley S; Bowman JL; Andersen NH; Guan Z; Rudolph J; Raetz CR
    Biochemistry; 2005 Dec; 44(50):16574-83. PubMed ID: 16342948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
    Warmus JS; Quinn CL; Taylor C; Murphy ST; Johnson TA; Limberakis C; Ortwine D; Bronstein J; Pagano P; Knafels JD; Lightle S; Mochalkin I; Brideau R; Podoll T
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2536-43. PubMed ID: 22401863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
    Cuny GD
    Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.
    Gao N; McLeod SM; Hajec L; Olivier NB; Lahiri SD; Bryan Prince D; Thresher J; Ross PL; Whiteaker JD; Doig P; Li AH; Hill PJ; Cornebise M; Reck F; Hale MR
    Protein Expr Purif; 2014 Dec; 104():57-64. PubMed ID: 25240855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.